Long term treatment of advanced endometrial cancer with lenvatinib and pembrolizumab

This case underscores the potential for long-term disease control with lenvatinib and pembrolizumab in advanced endometrial cancer, even in patients with proficient mismatch repair (pMMR) and low tumor mutational burden. Although toxicities can require treatment adjustments, they can often be effectively managed, allowing for prolonged therapy. Further research is needed to determine the optimal treatment duration and strategies to mitigate long-term side effects.